Predictive Oncology Inc. announced a collaboration with FluGen to bring an intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD). Through a proprietary design of experiments, the Predictive Oncology biologics team will be developing a formulation that is soluble and stable in a refrigerated state, which is a vital part in the drug development process. Most importantly, this addresses the need for a longer vaccine shelf-life to support global distribution including remote locations.

Predictive Oncology?s biologics capabilities are uniquely suited to help achieve maximum stability, one of the initial critical milestones.